VERAXA Biotech AG (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager (“BiTAC-TCE”) program through a collaboration with ATUM. ATUM will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines supporting IND/CTA-enabling activities and future clinical development. This collaboration follows encouraging preclinical data presented at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting and is intended to support CMC development, including early process, analytical and formulation development, as well as the production of material for nonclinical studies.
VERAXA’s BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. The company believes this conditional “AND”-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window. This innovative mechanism addresses a key challenge in cancer immunotherapy: the balance between efficacy and safety. Traditional T-cell engagers can attack healthy tissues, leading to severe side effects. By requiring dual target engagement, VERAXA’s approach aims to spare normal cells and enhance the therapeutic index.
The initiation of cell line development marks a critical milestone in advancing the BiTAC-TCE program toward clinical trials. Stable cell lines are essential for producing consistent, high-quality biologics for regulatory filings and eventual patient use. The collaboration with ATUM leverages their proprietary Leap-In Transposase technology, which is known for efficient and stable gene integration, potentially accelerating the timeline to IND submission.
For the biotech industry, this development underscores the growing interest in conditional activation strategies to improve the safety profile of immunotherapies. If successful, VERAXA’s BiTAC platform could set a new standard for T-cell engagers, enabling treatment of solid tumors that are currently difficult to target without significant toxicity. Investors and analysts will be watching for further updates on preclinical efficacy and the progress of cell line development.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company is building a pipeline of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
